A review of malaria vaccine clinical projects based on the WHO rainbow table - Wikidata - wikimedia - TriplyDB

A review of malaria vaccine clinical projects based on the WHO rainbow table

A review of malaria vaccine clinical projects based on the WHO rainbow table

http://www.wikidata.org/entity/Q21034112

about

Immune mechanisms in malaria: new insights in vaccine development Need of cost-effective vaccines in developing countries: What plant biotechnology can offer?The Use of Synthetic Carriers in Malaria Vaccine Design Malaria endemicity and co-infection with tissue-dwelling parasites in Sub-Saharan Africa: a review Application of radiation technology in vaccines development Profiling the host response to malaria vaccination and malaria challenge Paths to a malaria vaccine illuminated by parasite genomics Vaccines against malaria Recent advances in malaria drug discovery A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates TpUB05, a Homologue of the Immunodominant Plasmodium falciparum Protein UB05, Is a Marker of Protective Immune Responses in Cattle Experimentally Vaccinated against East Coast Fever Regulation of Plasmodium falciparum development by calcium-dependent protein kinase 7 (PfCDPK7)Plasmodium falciparum merozoite surface protein 3: oligomerization, self-assembly, and heme complex formation Advances in genetics and genomics: use and limitations in achieving malaria elimination goals New targets for drug discovery against malaria Theoretical and experimental studies of new modified isoflavonoids as potential inhibitors of topoisomerase I from Plasmodium falciparum A member of the CPW-WPC protein family is expressed in and localized to the surface of developing ookinetes Yeast lysates carrying the nucleoprotein from measles virus vaccine as a novel subunit vaccine platform to deliver Plasmodium circumsporozoite antigen.Malaria vaccine: a step toward elimination.Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets.Malaria vaccine research and development: the role of the WHO MALVAC committee Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24 Plasmodium vivax antigen discovery based on alpha-helical coiled coil protein motif Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.Distinct patterns of diversity, population structure and evolution in the AMA1 genes of sympatric Plasmodium falciparum and Plasmodium vivax populations of Papua New Guinea from an area of similarly high transmission Dynamics in multiplicity of Plasmodium falciparum infection among children with asymptomatic malaria in central Ghana.Strategies for designing and monitoring malaria vaccines targeting diverse antigens Generation of rodent malaria parasites with a high mutation rate by destructing proofreading activity of DNA polymerase δ.Allelic Forms of Merozoite Surface Protein-3 in Plasmodium falciparum Isolates From Southeast of Iran.Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis Vaccination with lipid core peptides fails to induce epitope-specific T cell responses but confers non-specific protective immunity in a malaria model High-throughput tri-colour flow cytometry technique to assess Plasmodium falciparum parasitaemia in bioassays.Dual fluorescent labelling of the human malaria parasite Plasmodium falciparum for the analysis of the ABC type transporter pfmdr2.Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines.Disruption of cellular homeostasis induces organelle stress and triggers apoptosis like cell-death pathways in malaria parasite Assessment of the neutrophilic antibody-dependent respiratory burst (ADRB) response to Plasmodium falciparum Efficacy of Phase 3 Trial of RTS, S/AS01 Malaria Vaccine in infants: a systematic review and meta-analysis.A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.The case for a rational genome-based vaccine against malaria.

P2860

Q21032484-D73345BB-5CB9-47B8-A58F-3FA8D1150598 Q26769942-A17ABB33-0D96-4E60-A606-47D80119F627 Q26777053-FA9E0952-3EB3-45CB-845D-5AF5DA3EBC10 Q26786020-D551B22A-5238-48E3-A65B-582B5ECAC924 Q26798165-2549A154-D63E-41E4-BBBB-A728BE3171FF Q26800494-00B535CA-9500-4E73-8C90-ECBF88CDE868 Q26853267-E65F4828-F983-4D40-82FA-70F8F136ABFC Q26995079-08D0085A-4BC2-4923-A9B3-049A63B39414 Q27010534-3BDB11FC-D61E-44A4-A4EB-66BEE9F5E6B3 Q27303293-0FC0930D-F3D6-4ED4-A879-0A63282ED539 Q27305881-DBB4F29A-34A6-4FA0-915E-DB929AC4B4B5 Q27972855-B1DE2A1B-DF66-4E70-8185-B3464264553A Q27974527-FEAE6682-B2BC-402F-80B4-1BF3120DC149 Q28082023-6CF560B1-B215-4500-82D4-68E08EF483E2 Q28489108-2C3EEE34-EF69-49E0-BC72-BA8B962EE786 Q28541220-FCA56AAE-0BD7-4F90-9451-7A34CD9C94C6 Q30042193-82C05B90-454E-4445-A603-DC0D6CF1E142 Q32175658-2825BC0E-E860-4E8F-95C4-2B9955B2D691 Q33577978-429CC0F7-A5D2-4A69-82D5-4512A9DAF39E Q33590453-E2D4D26D-F73F-4AB1-B747-D52875286958 Q33611463-566EA03C-1076-4611-BF51-47A7EB5DAB2F Q33743450-F753DC22-DF39-441D-9B32-8E79185E57F3 Q33800285-C6DB8668-BC7A-4694-A215-D4BC381E461A Q33855899-7A171B75-EDB4-409E-9CDA-18D21A7AABD0 Q33859217-C3DCD6C7-C9AF-4854-95CD-4946343097F7 Q33913006-85E74072-BF36-4F6D-97B0-518461D4B74A Q33959038-6B089CEB-5EF9-44CD-BF74-301EB6747674 Q34040908-F8DB6286-6636-4A8D-B0D4-B4340F2A470C Q34068587-6C6D73A2-C5B3-41F9-8AEA-D253E4DA9CD2 Q34234390-724010E0-A417-4509-BE17-7F823CB8B14D Q34398787-E99A2D28-4ABF-4890-BC65-0CADDF544292 Q34423023-C7761BC7-E2A3-436F-AB2F-BFF561E26A0E Q34471140-AA1D684B-96BB-48A9-8581-C2765D6AE34D Q34478487-3EDF4551-1898-45E8-A266-E2C0D34E39C8 Q34483288-195B6170-FD79-48C3-B532-C48A0EE4B3B5 Q34484078-8FE27D54-C458-4285-B89D-6F21C44AABF7 Q34548672-D6E89BEF-7E1E-4491-B2E8-0B3DB123CB65 Q34734075-C3C9816D-6B5B-45E1-9FBA-A78474CE7134 Q34749432-327FE337-3461-495C-81C7-49E6F8EDD50B Q34999392-E9015EE0-ACCD-44FD-AC83-5BB6A2390FC4

P2860

A review of malaria vaccine clinical projects based on the WHO rainbow table

http://www.wikidata.org/entity/Q21034112

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

A review of malaria vaccine clinical projects based on the WHO rainbow table

@ast

A review of malaria vaccine clinical projects based on the WHO rainbow table

@en

A review of malaria vaccine clinical projects based on the WHO rainbow table

@en-gb

A review of malaria vaccine clinical projects based on the WHO rainbow table

@nl

type

label

A review of malaria vaccine clinical projects based on the WHO rainbow table

@ast

A review of malaria vaccine clinical projects based on the WHO rainbow table

@en

A review of malaria vaccine clinical projects based on the WHO rainbow table

@en-gb

A review of malaria vaccine clinical projects based on the WHO rainbow table

@nl

prefLabel

A review of malaria vaccine clinical projects based on the WHO rainbow table

@ast

A review of malaria vaccine clinical projects based on the WHO rainbow table

@en

A review of malaria vaccine clinical projects based on the WHO rainbow table

@en-gb

A review of malaria vaccine clinical projects based on the WHO rainbow table

@nl

P1433

Q21034112-042DB726-4229-4F76-9EEB-431A73DF94D4

P1476

Q21034112-9750E317-92D9-465B-9D28-EBD86BC4B912

P2093

Q21034112-BF2F9147-9E89-4D43-9C35-0E09DCDEB698

P275

Q21034112-DFDD6A3C-E532-40EB-9D40-BF44F546949E

P2860

Q21034112-01A699C7-6473-4008-B290-BD8ED9751FFF

Q21034112-03AE356F-D3BD-4783-A9AB-76B8F2256478

Q21034112-059DC091-8968-430E-B0CC-84C6FFD221BD

Q21034112-06C41EE5-3618-42E9-8F10-A53ED8599F53

Q21034112-09BCE1AC-016E-45CE-9403-1BA579781750

Q21034112-0A14E231-A424-4D33-ABF3-2C6227E9EBFC

Q21034112-0A245902-E698-483A-B258-FB251741912A

Q21034112-0A270B82-7940-4E49-8D67-CB7ACA986410

Q21034112-0B5F37E5-5C72-4508-B278-D7B26AB73FF3

Q21034112-0BBEDD59-34C6-41CE-BCA0-AC0440B46FF3

P2888

Q21034112-6AEE5F5A-94D4-4C80-AF23-AB5CCBCE8333

P304

Q21034112-61001A7B-38BA-466D-B937-D2858DC17826

P31

Q21034112-8751C555-75AA-4A29-B262-162D0FB6F5AE

Q21034112-893F7DB6-BAB1-48A4-BB35-4A258215F81C

P3181

Q21034112-BDC8F20C-ED5D-48DA-8DB4-351F49DCB95C

P356

Q21034112-59B83B6C-8EC5-4CEC-A6CF-DE6245520E04

P407

Q21034112-145F48A2-8C7F-4769-A5D5-24DFDA800D42

P433

Q21034112-FD3C8848-C67B-4175-921E-DF198FE8AA81

P478

Q21034112-EB7581EE-47A8-4CE9-A59D-8302E0970DFD

P50

Q21034112-20D4F470-047E-4B6D-BB2B-28B3BC18E8A4

Q21034112-2769132C-808A-4B9C-9504-2EAEFECB362E

Q21034112-9BD3BBF4-12BC-4A30-BCE0-E5D54919ABEA

P5008

Q21034112-32DD1569-BF84-4631-86F1-D27012D7AF21

P577

Q21034112-EE015AA6-FF46-4ECE-951A-A0C773CE998B

P5875

Q21034112-4F5AD2EE-4EF7-4F89-8C03-1AE8A7225298

P6179

Q21034112-64BB9A0F-2C90-472A-AC41-343AFEB1A3FB

P698

Q21034112-13F7DD3C-27C4-4891-B69F-4F824035EC47

P921

Q21034112-17E63CE8-3C8D-4572-A438-AB41EF3713E9

Q21034112-257ED3C0-FE11-4BD1-AFF4-7189AF3BD588

Q21034112-50F70E4F-88CF-457C-89C1-C2EC00F6DB2E

Q21034112-C1D5C8E9-020D-4407-B0AB-3717DF5F2FCD

P932

Q21034112-AD5DCE7E-7C50-47EC-9FA0-C8C4E9390FB6

P3181

P356

1475-2875-11-11

P1433

Malaria Journal

P1476

A review of malaria vaccine clinical projects based on the WHO rainbow table

@en

P2093

Lauren Schwartz

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Vaccines for preventing malaria (SPf66)

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria

Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

The RTS,S malaria vaccine

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children

Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component

P2888

1475-2875-11-11

P304

11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2550148

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1475-2875-11-11

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Graham V. Brown

P5008

P577

2012-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221733885

http://www.w3.org/2001/XMLSchema#string

P6179

1024029582

http://www.w3.org/2001/XMLSchema#string

P698

22230255

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

biomedical investigative technique

Alþjóðaheilbrigðismálastofnunin

P932

3286401

http://www.w3.org/2001/XMLSchema#string